135 related articles for article (PubMed ID: 8092825)
1. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa.
McFarland MM; Scott EM; Li Wan Po A
Antimicrob Agents Chemother; 1994 Jun; 38(6):1271-6. PubMed ID: 8092825
[TBL] [Abstract][Full Text] [Related]
2. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa.
Wu YL; Scott EM; Po AL; Tariq VN
J Antimicrob Chemother; 1999 Sep; 44(3):389-92. PubMed ID: 10511408
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
[TBL] [Abstract][Full Text] [Related]
4. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
Chan EL; Zabransky RJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
Johnson M; Miniter P; Andriole VT
J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631
[TBL] [Abstract][Full Text] [Related]
6. Effects of inoculum size on the activity of carboxy- and ureido-penicillins and effects of combinations of ureido-penicillins with aminoglycosides against resistant Pseudomonas aeruginosa.
Watanakunakorn C
J Antimicrob Chemother; 1986 Jan; 17(1):91-5. PubMed ID: 3081474
[TBL] [Abstract][Full Text] [Related]
7. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
8. Single daily dosing of amikacin in an in-vitro model.
Dudley MN; Zinner SH
J Antimicrob Chemother; 1991 May; 27 Suppl C():15-9. PubMed ID: 1906862
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ciprofloxacin alone and in combination with azlocillin in experimental endocarditis due to Pseudomonas aeruginosa.
Thauvin C; Lecomte F; Le Boete I; Grise G; Lemeland JF
Infection; 1989; 17(1):31-4. PubMed ID: 2493429
[TBL] [Abstract][Full Text] [Related]
10. Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model.
den Hollander JG; Horrevorts AM; van Goor ML; Verbrugh HA; Mouton JW
Antimicrob Agents Chemother; 1997 Jan; 41(1):95-100. PubMed ID: 8980762
[TBL] [Abstract][Full Text] [Related]
11. Activities of tobramycin and azlocillin alone and in combination against experimental osteomyelitis caused by Pseudomonas aeruginosa.
Norden CW; Shaffer MA
Antimicrob Agents Chemother; 1982 Jan; 21(1):62-5. PubMed ID: 6805423
[TBL] [Abstract][Full Text] [Related]
12. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
Strunk RW; Gratz JC; Maserati R; Scheld WM
Antimicrob Agents Chemother; 1985 Sep; 28(3):428-32. PubMed ID: 2934021
[TBL] [Abstract][Full Text] [Related]
13. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
[TBL] [Abstract][Full Text] [Related]
14. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
15. [Bacteriostatic activity of azlocillin, gentamycin, amikacin singly or in combination on 200 strains of Pseudomonas aeruginosa].
Texier-Maugein J; Fourche J; Mormede M; Mazaud C; Bébéar C
Pathol Biol (Paris); 1986 May; 34(5):415-8. PubMed ID: 3095774
[TBL] [Abstract][Full Text] [Related]
16. Synergy of azlocillin with aminoglycosides.
Chin NX; Neu HC
J Antimicrob Chemother; 1983 May; 11 Suppl B():33-8. PubMed ID: 6413482
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of azlocillin-cefotaxime and azlocillin-tobramycin combinations against blood and multi-drug resistant bacterial isolates.
Fass RJ
Antimicrob Agents Chemother; 1982 Jul; 22(1):167-9. PubMed ID: 6289737
[TBL] [Abstract][Full Text] [Related]
18. In vitro inhibitory and bactericidal activity of cefpiramide and seven antipseudomonal agents against Pseudomonas aeruginosa.
Pfaller M; Bale M; Preston T; Howard W; Koontz F
Diagn Microbiol Infect Dis; 1986 May; 5(1):17-23. PubMed ID: 3086026
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antibacterial activity of azlocillin and ticarcillin in vitro and in irradiated neutropenic mice.
van der Voet GB; Mattie H; van Furth R
J Antimicrob Chemother; 1985 Nov; 16(5):605-13. PubMed ID: 3935638
[TBL] [Abstract][Full Text] [Related]
20. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
